December 2010

Survey: relationship between FDA and life sciences industry deteriorating, delays in review process cited

Monday, December 13, 2010

Top biopharmaceutical company executives are frustrated with delays and inconsistencies in the Food and Drug Administration (FDA) regulatory review process and are concerned that passage of the healthcare reform law, which gave the already resource-constrained agency more responsibilities, will further complicate drug approvals, according to a new PricewaterhouseCoopers (PwC) survey.

[Read More]